首页> 美国卫生研究院文献>other >Pinellia pedatisecta Agglutinin Targets Drug Resistant K562/ADR Leukemia Cells through Binding with Sarcolemmal Membrane Associated Protein and Enhancing Macrophage Phagocytosis
【2h】

Pinellia pedatisecta Agglutinin Targets Drug Resistant K562/ADR Leukemia Cells through Binding with Sarcolemmal Membrane Associated Protein and Enhancing Macrophage Phagocytosis

机译:半夏 pedatisecta凝集素通过与肌膜相关蛋白结合并增强巨噬细胞吞噬作用靶向耐药性K562 / ADR白血病细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pinellia pedatisecta agglutinin (PPA) has previously been used in labeling fractions of myeloid leukemia cells in our laboratory. We report here that a bacterial expressed recombinant PPA domain b tagged with soluble coxsackie and adenovirus receptor (sCAR-PPAb) preferentially recognized drug resistant cancer cells K562/ADR and H460/5Fu, as compared to their parental cell lines. Pretreatment of K562/ADR cells with sCAR-PPAb significantly enhanced phagocytosis of K562/ADR by macrophages in vivo. Meanwhile, in a K562/ADR xenograft model, intratumoral injection of sCAR-PPAb induced macrophage infiltration and phagocytosis. Furthermore, immunoprecipitation, mass spectrometry and Western blot identified the membrane target of PPA on K562/ADR as sarcolemmal membrane associated protein (SLMAP). An antibody against SLMAP significantly promoted the phagocytosis of K562/ADR by macrophages in vitro. These findings suggest that PPA not only could be developed into a novel agent that can detect drug resistant cancer cells and predict chemotherapy outcome, but also it has potential value in immunotherapy against drug resistant cancer cells through inducing the tumoricidal activity of macrophages.
机译:半夏半乳糖凝集素(PPA)以前已在我们的实验室中用于标记髓样白血病细胞的组分。我们在这里报告,细菌表达的重组PPA结构域b标记有可溶性柯萨奇和腺病毒受体(sCAR-PPAb)优先识别耐药性癌细胞K562 / ADR和H460 / 5Fu,与其亲本细胞系相比。用sCAR-PPAb预处理K562 / ADR细胞可显着增强体内巨噬细胞对K562 / ADR的吞噬作用。同时,在K562 / ADR异种移植模型中,肿瘤内注射sCAR-PPAb诱导巨噬细胞浸润和吞噬作用。此外,免疫沉淀,质谱和Western印迹法将K562 / ADR上PPA的膜靶标定为肌膜相关蛋白(SLMAP)。抗SLMAP的抗体在体外可显着促进巨噬细胞对K562 / ADR的吞噬作用。这些发现表明PPA不仅可以发展成为可以检测耐药性癌细胞并预测化疗结果的新型药物,而且还可以通过诱导巨噬细胞的杀伤活性而在针对耐药性癌细胞的免疫治疗中具有潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号